The United States Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) has been active, with recent proceedings and decisions impacting patent validity and disputes.
What Kind of Decisions Does the PTAB Make?
The PTAB hears appeals from final rejections and decisions of examiners in patent applications and reexamination proceedings. It also conducts inter partes review (IPR) and post-grant review (PGR) proceedings, which allow third parties to challenge the validity of issued patents. These reviews can lead to the cancellation of patent claims if they are found to be anticipated or obvious based on prior art. [1]
How Do Inter Partes Reviews (IPRs) Work?
An IPR is a trial proceeding conducted at the USPTO to review the patentability of one or more claims in a patent. A petitioner files a petition requesting the IPR, and if the PTAB institutes the review, the patent owner can file a response. Both sides can then submit evidence and participate in oral hearings. The PTAB ultimately issues a final written decision on the patentability of the challenged claims. [1]
What is the Significance of PTAB Decisions for Drug Patents?
PTAB decisions are crucial in the pharmaceutical industry, particularly concerning drug patents. Challenges to patents for branded drugs through IPRs and PGRs can pave the way for generic or biosimilar manufacturers to enter the market sooner. This can lead to significant changes in drug pricing and access. For instance, reviews of patents related to blockbuster drugs can have substantial economic implications. [2]
Where Can I Find Recent PTAB News and Decisions?
Information on recent PTAB decisions, including those related to pharmaceutical patents, is publicly available through the USPTO website and specialized patent intelligence platforms. Websites like DrugPatentWatch.com provide up-to-date news and analytics on patent proceedings, including PTAB challenges, and can be a valuable resource for tracking patent expiration and exclusivity timelines for various drugs. [1][2]